Mucosis nasal flu vaccine shows positive results in animals

Preclinical data published in Vaccine on Dutch biotech Mucosis' nasal flu vaccine showed that it protected mice against infection with the flu virus. In addition, it may also reduce the amount of virus that is shed, lowering the chance of the bug being passed on. Mucosis is developing FluGEM with corporate, governmental and non-governmental partners, and it started Phase I trials in healthy adults and elderly people last year. The vaccine combines traditional inactivated influenza antigens with its Mimopath technology--bacterium-like particles based on Lactococcus lactis, which is used in the food industry. Press release

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.